Audio BioStock previously have reported on announced the Swedish biopharmaceutical company Cereno Scientific at the end of January that it had obtained two new patents for its clinical phase II candidate CS1 – a drug based on a reformulation of valproic acid intended to treat cardiovascular diseases, including the rare disease pulmonary arterial hypertension (PAH). The patents are part of two different patent families; a patent related to the first family was granted in Canada, while a patent related to the second family was granted in Russia.
The patent granted in the Russian market is part of Cereno's second patent family for the drug candidate CS1. The patent is called Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation and is valid until 2035, with the possibility of an extension for another five years.
New patent for the Japanese market
This patent family also covers the American market, and this week Cereno Scientific announced that it has extended its protection for this family of patents to the Japanese market, which is one of the largest pharmaceutical markets in the world.
In a press release, the company's CEO commented Sten R. Sörensen The importance of the new patent:
»Japan is one of the world's largest pharmaceutical markets, second only to the US and marginally to China. The patent protection for CS1, which now covers two of the most important global markets, is an attractive patent position for future development.«
Strengthened commercial positioning
In a recent interview with BioStock, Cereno Scientific's Chief Intellectual Property Officer (CIPO) emphasized Jonas Faijerson Säljö the importance of a good IPR (intellectual property rights) strategy and said that he expected the company to obtain more patents:
»By having a strong patent strategy, we are both thinking about strengthening Cereno's commercial position in potential partnering discussions and at the same time considering the longer-term perspective in relation to potential commercial competitors. "
Cereno Scientific continues preparations for a Phase II study with CS1 in PAH and the study is expected to begin in mid-2021. In January, the company entered into a collaboration with the contract research organization (CRO) Worldwide Clinical TrialsThrough the collaboration, Worldwide Clinical Trials will provide the company with valuable support and guidance in the final preparations for the clinical trial, e.g. by providing input in determining the study protocol, submitting the IND application to the FDA, and preparing clinical centers in the US, prior to conducting the Phase II study with CS1 in PAH. Read more.
The new patent is another important addition to the growing IPR portfolio secured for Cereno Scientific's assets and is an important contribution in the work to strengthen the company's commercial positioning.
The content of BioStock's news and analysis is independent, but BioStock's operations are to some extent financed by companies in the industry. This post refers to a company from which BioStock has received funding.